CA
NZ
UK
AU
IND
US
Aprea Therapeutics, Inc. (NASDAQ:APRE) has spent 2026 doing something unusual for a micro-cap biotech: raising money, then immediately spending it on speed. Its second-quarter results, published on 12 August 2026, read less like a routine financial statement than a progress report on a deliberate …
Bionano Genomics, Inc. (NASDAQ:BNGO) has spent two years shrinking in order to survive. On 10 August 2026 the San Diego company reported second-quarter results showing the other side of that process: revenue growing again, grossMarginabove 50%, and no securedDebton the balance sheet.
Aclarion, Inc. (NASDAQ:ACON) has an unusual problem: an activist investor tried to buy the company for more than the market would pay, and the board said no. The ColoradoMedTechsells Nociscan, a magnetic resonance spectroscopy (MRS) test that reads chemical signals inside spinal discs to …
● Zentalis Pharmaceuticals shares fell roughly 6.5% in after-hours trading following a dilutive share offering.
● Prime Medicine is a Cambridge, Massachusetts-based gene-editing biotech built around Prime Editing, a precision DNA-rewriting technology.
● Rocket Pharmaceuticals is a commercial-stage gene-therapy company built around treatments for ultra-rare genetic diseases.
● The company achieved a GenentechPartnershipmilestone, a positive development overshadowed by broader cash burn concerns.
● Editas Medicine has spent the past 20 months rebuilding itself around a single new strategic direction.
● CVRx shares closed at $2.94 on August 13, 2026, up 7.69% on the day, rebounding after an earlier decline.
● AirSculpt Technologies reported second-quarterRevenuebelow the roughly $44.2 million analysts had modeled, coming in under $44.0 million a year earlier.
Please wait processing your request...